Newly Opened Clinical Trial: The BEACON Study (Breast Cancer Outcomes with NKTR-102)

The Weill Cornell Breast Center has recently opened a new clinical trial for women with locally recurrent or metastatic breast cancer that was previously treated with anthracycline, a taxane, and capecitabine. The study sponsor is Nektar Therapeutics. The principal investigator at Weill Cornell is Dr. Tessa Cigler. For more information about the study, please call Marta Cobham, RN at (212) 821-0780 or e-mail Marta at mac2034@med.cornell.edu.

Study Details

The purpose of the study is to test how well women with breast cancer respond to treatment with the experimental drug NKTR-102, compared to standard treatments for breast cancer. The study will also look at the side effects of the study drug and examine how long NKTR-102 stays in a patient’s blood.

Treatment Plan

Study participants will be randomly assigned to one of two study arms:

  • Arm A: participants will receive NKTR-102 via infusion on Day 1 of each 21 day cycle.
  • Arm B: participants will receive one of seven standard of care treatment options available at the study center. The choice of treatment in Arm B will be made after discussions with your doctor. Depending on which drug is chosen by you and your doctor, cycles in Arm B will be either 21 days or 28 days.

The study will take about 38 months to complete. The amount of time on study depends on how well a participant responds to study treatment.

Key Eligibility

  • Women age 18 and older
  • Diagnosed with breast cancer
  • Locally recurrent or metastatic disease
  • Prior therapy must have included anthracycline, a taxane, and Xeloda; must have received a minimum of 2 and maximum of 5 prior cytoxic chemotherapy regimens
  • Detailed eligibility reviewed when you contact the study team

New Clinical Trial: Panobinostat and Letrozole in Treating Metastatic Breast Cancer

N093B: Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients with Triple Negative Metastatic Breast Cancer

The Weill Cornell Breast Center has recently opened a new clinical trial for people with metastatic breast cancer that is considered “triple negative,” meaning breast cancer that does not express genes for estrogen receptor (ER), progesterone receptor (PR) or HER2. The study sponsor is the Cancer Trials Support Unit (CTSU)/North Central Cancer Treatment Group. The principal investigator at Weill Cornell is Dr. Tessa Cigler. For more information about the study, please call Marta Cobham, RN at (212) 821-0780 or e-mail Marta at mac2034@med.cornell.edu.

Study Details

The purpose of this study is to determine how well people with metastatic breast cancer respond to treatment with the experimental drug panobinostat (also called LBH589) when it is given with letrozole. The study will also evaluate the safety of panobinostat when combined with letrozole.

Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving panobinostat together with letrozole may be an effective treatment for breast cancer.

Treatment Plan

Treatment cycles in this study are 28 days. Study participants will take panobinostat (as a tablet by mouth) once daily on Days 1, 3 and 5 in weeks 1-4 and oral letrozole once daily on days 1-28. Treatment cycles repeat every 28 days as long as participants are responding to treatment and tolerating the medications. After completing study therapy, participants will be followed up every 3 to 6 months for up to 5 years.

Key Eligibility

  • Men and women with metastatic breast cancer
  • Cancer must be unresected (has not been removed by surgery)
  • Women must be postmenopausal based on one of the following criteria:
    • Age 60 or older
    • Age 45 or older with last menstrual period ≥12 months before entering the study
    • Bilateral oophorectomy (surgical removal of both ovaries)
  • Men must be age 18 or older
  • Prior therapy:
    • Zero or 1 prior chemotherapy regimens for breast cancer (no more than 1 prior chemotherapy regimen)
    • ≤2 prior aromatase inhibitor regimens (including letrozole)
  • Detailed eligibility reviewed when you contact the study team

What’s New in Metastatic Breast Cancer: Dr. Moore and Dr. Vahdat’s Presentations

This slideshow requires JavaScript.

At a seminar on June 21, 2012,  Dr. Anne Moore, Medical Director of the Weill Cornell Breast Center, and Dr. Linda Vahdat, Director of Research at the Breast Center, reported on the most promising and exciting news from the recent ASCO conference for those living with metastatic breast cancer.

Click below to view the slides from Dr. Moore’s and Dr. Vahdat’s presentations.


Report from ASCO Seminar: What’s New in Metastatic Breast Cancer?

A seminar with Dr. Anne Moore, Dr. Linda Vahdat and SHARE (Self-Help for Women with Breast or Ovarian Cancer)

Oncologists from around the globe share the newest discoveries in cancer research at “Collaborating to Conquer Cancer,” the annual meeting of the American Society of Clinical Oncology (ASCO) at the beginning of June 2012.

The Breast Center’s Dr. Anne Moore and Dr. Linda Vahdat will report on the highlights of ASCO, consolidating the most promising and exciting news into information that is meaningful for those living with metastatic breast cancer. Dr. Moore and Dr. Vahdat are actively involved in breast cancer research at the national and local level.

Dr. Moore is the Medical Director of the Weill Cornell Breast Center.
She is a Professor of Clinical Medicine at the Weill Medical College and Attending Physician at The New York Presbyterian Hospital.

Dr. Vahdat is a Professor of Medicine, Weill Cornell Medical College and
Director of Research at the Breast Center.

When

Thursday June 21, 6pm to 7:30 pm

Where

Weill Greenberg Conference Center
1305 York Avenue at 70th Street, Room B & C

REFRESHMENTS PROVIDED

To register or for more information call (212) 719-2943 or e-mail rsvp@sharecancersupport.org